Articles tagged with “fda-ai-guidance”

A 2026 analyst guide to AI governance in biotech: council charter templates, decision rights (RACI), FDA/EMA principles, EU AI Act deadlines, and six company case studies.

A 2026 analyst guide to building an AI Center of Excellence in biotech: hub-spoke-hybrid models, FDA/EMA/NIST governance, staffing budgets from $2M to $200M, and named cases from Sanofi, Merck, Novartis, AstraZeneca, and GSK.

A 2026 framework for biotech AI strategy: a five-axis prioritization matrix, FDA/EMA risk tiering, data readiness benchmarks, ROI data, and five named case studies including Insilico, Recursion, and Xaira.

Analyst report on AI in preclinical development in 2026: market size, FDA credibility framework and animal-testing roadmap, organ-on-chip adoption, and five named case studies.

Analyze the FDA AI early-phase clinical trials RFI. This guide covers pilot program objectives, AI evaluation metrics, and evidence-based response strategies.

Review regulatory requirements for assembling pharma AI validation evidence packages. Examine FDA and EMA guidelines, credibility frameworks, and GxP rules.

Examine the architectural design and compliance framework for AI governance in pharmacovigilance, including FDA and EU regulatory guidelines for drug safety.